Summary
Fifty-five patients with carcinoma in situ of the bladder have been treated with intravesical Adriamycin, the longest follow-up being over 2.5 years. Side-effects were negligible. Primary carcinoma in situ shows the highest overall response rate, with over 80%, followed by secondary carcinoma in situ with no tumours, with 67%; in the presence of active tumour only 25% of patients treated showed any real improvement. Adriamycin is recommended for the conservative management of primary carcinoma in situ.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Althausen AF, Prout G Jr, Daly JJ (1976) Non-invasive papillary carcinoma of the bladder associated with carcinoma-in situ. J Urol 116: 575
Daly JJ (1976) Carcinoma-in-situ of the urothelium. Urol Clin North Am 3: 87
Farrow GM, Utz DC, Rife CC, et al (1977) Clinical observations on sixty-nine cases of in-situ carcinoma of the urinary bladder. Cancer Res 37: 2794
Jakse G, Margerger H (1982) Topical adriamycin therapy for carcinoma-in-situ of the urinary bladder. A follow-up. Paper presented at the Fifth Congress of the European Association of Urology, Vienna
Skrabanek P, Walsh A (eds) (1981) Bladder Cancer. IUCC, Geneva, p 32 (Technical report series no. 60)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Glashan, R.W. Treatment of carcinoma in situ of the bladder with doxorubicin (Adriamycin). Cancer Chemother. Pharmacol. 11 (Suppl 1), S35–S37 (1983). https://doi.org/10.1007/BF00256715
Issue Date:
DOI: https://doi.org/10.1007/BF00256715